Dergiler / Journal of Health Sciences and Medicine / 2023 / Cilt: 6 - Sayı: 1

The effect of thyroid hormone withdrawal performed to evaluate the success of I-131 ablation on quality of life and psychological symptoms in female patients with low-risk differentiated thyroid cancer

Sayfa
66–72
Yayın Tarihi
2023-01-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

To reduce the side effects of hypothyroidism, treatment response assessment with TSH stimulation should be used only in a selected group of patients.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aim: There is a need to evaluate the treatment response in patients who have undergone radioiodine treatment (RIT) for differentiated thyroid cancer.
📊
Temel Bulgular & Veri:Diagnostic tests that are used for this purpose include radioiodine whole-body scan (WBS) and serum thyroglobulin (Tg) measurement, which are most accurate during thyroid-stimulating hormone (TSH) stimulation.
💡
Sonuç & Katkı:To reduce the side effects of hypothyroidism, treatment response assessment with TSH stimulation should be used only in a selected group of patients.
🔬Tür:Uygulamalı Anket & Alan Araştırması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Thyroid cancer · hypothyroidism · life quality

Abstract

Aim: There is a need to evaluate the treatment response in patients who have undergone radioiodine treatment (RIT) for differentiated thyroid cancer. Diagnostic tests that are used for this purpose include radioiodine whole-body scan (WBS) and serum thyroglobulin (Tg) measurement, which are most accurate during thyroid-stimulating hormone (TSH) stimulation. However, temporary discontinuation of thyroid hormone therapy to increase TSH (withdrawal) may be associated with the morbidity of hypothyroidism. The study aimed to show the effects of thyroid hormone withdrawal (THW) on quality of life and psychological symptoms in female patients with low-risk, well-differentiated papillary thyroid cancer. Material and Method: We applied the short form-36 (SF-36) and Symptom Checklist-90-R (SCL-90-R) questionnaires to the patients in the euthyroid state who have referred a median of 9 months (6-13 months) after RIT to perform a dWBS and to evaluate stimulated Tg. We applied the same questionnaire again when thyroid-stimulating hormone (TSH) was > 30 μIU/mL 4 weeks after THW (hypothyroid state). Results: 52 patients were evaluated (median age 48 years, range 23-65 years). There was a statistically significant worsening in anxiety, psychosis, additional items, and general symptoms of the SCL-90-R questionnaire. With the SF-36 questionnaire, we observed statistically significant worsening in physical functioning, role limitation due to physical health, energy/fatigue, emotional well-being, social functioning, and general health change. Conclusion: THW worsened the patients’ psychological symptoms and quality of life. To reduce the side effects of hypothyroidism, treatment response assessment with TSH stimulation should be used only in a selected group of patients.

🔖

Bu Makaleye Atıf Yap

KUPIK, O., ŞEN, B., ARPA, M., AVCI, U., GÜNDOĞDU, H., KALCAN, S., GÜÇER, H., AKIN, Ş., TUNCEL, M. (2023). The effect of thyroid hormone withdrawal performed to evaluate the success of I-131 ablation on quality of life and psychological symptoms in female patients with low-risk differentiated thyroid cancer. Journal of Health Sciences and Medicine, Cilt: 6 - Sayı: 1, 66–72. https://ajindex.com/articles/876377

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Mazzaferri EL. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 1999; 9: 421-7.
  2. Tan LG, Nan L, Thumboo J, Sundram F, Tan LK. Health‐related quality of life in thyroid cancer survivors. Laryngoscope 2007; 117: 507-10.
  3. Lamartina L, Leboulleux S, Terroir M, Hartl D, Schlumberger M. An update on the management of low-risk differentiated thyroid cancer. Endocr Relat Cancer 2019; 26: R597-R610. Reiners C, Dietlein M, Luster M. Radio-iodine therapy in differentiated thyroid cancer: indications and procedures. Best Pract Res Clin Endocrinol Metab 2008; 22: 989-1007.
  4. Torlontano M, Crocetti U, D'Aloiso L, et al. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. Eur J Endocrinol 2003; 148: 19-24.
  5. Berger F, Friedrich U, Knesewitsch P, Hahn K. Diagnostic 131 I whole-body scintigraphy 1 year after thyroablative therapy in patients with differentiated thyroid cancer: correlation of results to the individual risk profile and long-term follow-up. Eur J Nucl Med Mol Imaging 2011; 38: 451-8.
  6. Torlontano, M, Attard, M, Crocetti, U, et al. Follow-up of low risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases. J Clin Endocrinol Metab 2004; 89: 3402-7.
  7. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment. J Clin Endocrinol Metab 2002; 87: 1499-501.
  8. Mazzaferri EL, Robbins RJ, Spencer CA, et al. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1433-41.
  9. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016; 26: 1-133.
  10. Lee J, Yun MJ, Nam KH, Chung WY, Soh E-Y, Park CS. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma. Thyroid 2010; 20: 173-9.
  11. Schroeder PR, Haugen B, Pacini R, et al. A